Next Phase Newsletter

A wholly owned venture arm subsidiary of a regional health insurance firm seeks to invest in technologies that are a strategic fit with members of the insurer’s network. The firm is flexible in terms of investment sizes and considers an array of capital structures including equity, convertible note, debt, and others. The firm typically co-invests with other investors but is open to leading a financing round. The firm is currently seeking new opportunities from across the US, while non-US opportunities may also be considered.

The firm is focused on opportunities in the following areas: Accountable Care Organizations, Consumer Solutions; Health Information Technology; and Behavioral Health. Potential examples may include consumer-facing patient engagement software, behavioral health technology, telemedicine, and B2B solutions that help healthcare organizations with decision making and financial planning. The firm is stage agnostic and would consider from pre-revenue to commercial-stage companies. Historically the firm has invested in patient monitoring system, EHR aggregation and analytics, and mobile health information platform.

The firm is seeking experienced, competent teams with disruptive innovations that are a strategic fit with its parent company’s network members. After investment, the firm typically requests a board seat or at least an observer position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based firm is investing from a multi-million dollar evergreen fund and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests primarily in the USA and Canada.

The firm is presently focused on technologies that involve an IT/software component, across digital health, healthcare services, medtech, and diagnostics. The firm is open to opportunities in any clinical indication, especially ocular. The firm is only interested in devices and diagnostics that have in-human data, have received marketing approval and are in the commercialization stage.

In the life science sector, the firm is not interested in early-stage R&D opportunities; howeverthe firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that is based in Beijing, China focuses on medical device technologies. The firm was formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$15 million. Typical investment size ranges from US$1-5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however it can aid in identifying strategic partners in the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major global pharma firm is interested in forming partnerships with small biotech companies using a variety of structures depending on the needs of the opportunity, including licensing, development partnerships, co-marketing, and acquisitions. Partnerships may also involve in-kind services. The firm works with partners worldwide.

The firm is seeking transformational therapeutic opportunities across all disease areas. While the firm will consider assets in any indication area, immuno-oncology is an area of high interest; the firm is also particularly interested in other areas of immunology and in inflammation, metabolic disease (particularly type 2 diabetes), fibrosis and hypertension. However, any asset that demonstrates a major treatment effect for a serious disease condition will be considered.

The firm is open to any type of modality, including small molecules, biologics or cell therapies. The firm also has some interest in companion diagnostics and means of selecting suitable patients or monitoring patients. The firm will work with companies at any stage of development, from very early discoveries through to market.

The firm does not work with companies pursuing incremental innovations; the firm only partners on novel, breakthrough technologies, such as new molecules or new targets. The firm is interested in assets in which the mechanism of action is understood, and it is preferred that the target or pathway of the asset is validated. The firm is interested in assets that have been shown to have an unambiguous advantage, and which can create value for patients and payers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The proprietary venture capital and private equity arm of a leading asset management organization specializes in green-field, early and growth stage investments. With an evergreen fund structure, the firm can be flexible in terms of investment sizes (up to $250 million per deal) and horizon. The firm typically makes equity investments. The firm works with businesses based in China or with a China angle.

Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm headquartered in Hong Kong currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare-focused US$100 million evergreen fund based in Taipei, Taiwan seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$0.5 to 2 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from Taiwan, the US, and Canada.

Within healthcare, the firm considers broadly across the healthcare field, including biomedicine, medical devices, diagnostics, and healthcare IT. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. The firm does not require board representation after investment. As a financially-driven investor, the firm does not typically request regional rights, but it can provide assistance with finding local partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com